Payment overview · 2025
General Payments
$983.89
42 reported records · 11 companies
Healthcare provider profile · identity verified
Bryan Potthoff, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EDMOND, OK · NPI 1881829547
Verified facts
What the public records show
CMS Open Payments records show Bryan Potthoff, M.D. received $983.89 in general payments during 2025 across 42 reported records.
SHIELD THERAPEUTICS INC accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $233.39 | 23.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.43 | 16.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $155.06 | 15.8% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $138.95 | 14.1% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $78.09 | 7.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.56 | 7.2% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $50.67 | 5.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.55 | 3.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.59 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.44 | 1.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.16 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $983.89 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $233.39 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $140.31 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $138.95 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $125.76 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.29 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $99.47 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $78.09 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $54.18 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $54.18 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $50.67 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.47 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.59 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 618 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 81 |
| Lisinopril | Lisinopril | 293 | 80 |
| Omeprazole | Omeprazole | 239 | 54 |
| Losartan Potassium | Losartan Potassium | 210 | 65 |
| Metformin Hcl Er | Metformin Hcl | 191 | 49 |
| Simvastatin | Simvastatin | 182 | 52 |
| Gabapentin | Gabapentin | 164 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 49 |
| Meloxicam | Meloxicam | 145 | 37 |
| Trazodone Hcl | Trazodone Hcl | 144 | 33 |
| Potassium Chloride | Potassium Chloride | 123 | 36 |
| Sertraline Hcl | Sertraline Hcl | 119 | 28 |
| Allopurinol | Allopurinol | 109 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 25 |
| Ozempic | Semaglutide | 96 | 20 |
| Glipizide Er | Glipizide | 92 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 20 |
| Alendronate Sodium | Alendronate Sodium | 83 | 22 |
| Furosemide | Furosemide | 83 | 28 |
| Metformin Hcl | Metformin Hcl | 82 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 21 |
| Tramadol Hcl | Tramadol Hcl | 77 | 22 |
| Montelukast Sodium | Montelukast Sodium | 76 | 19 |
| Januvia | Sitagliptin Phosphate | 75 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 12 |
| Levetiracetam | Levetiracetam | 60 | suppressed |
| Jardiance | Empagliflozin | 59 | suppressed |
| Lamotrigine | Lamotrigine | 59 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | 12 |
| Buspirone Hcl | Buspirone Hcl | 53 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 14 |
| Trulicity | Dulaglutide | 51 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 22 |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Atenolol | Atenolol | 46 | 11 |
| Ezetimibe | Ezetimibe | 43 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Finasteride | Finasteride | 37 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Carvedilol | Carvedilol | 36 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 19 |
| Eliquis | Apixaban | 32 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 11 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 12 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $983.89 · 42 records | SHIELD THERAPEUTICS INC | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, INSPIRE, NURTEC ODT, Ozempic, PENMENVY, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, Veozah, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error